Author： Fagiolini Andrea Cañas Fernando Gallhofer Bernd Larmo Ilkka Levy Pedro Montes José Manuel Papageorgiou Georgios Zink Mathias Rossi Alessandro
Publisher： Informa Healthcare
ISSN： 1465-6566
Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.13, 2010-09, pp. : 2199-2220
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Ziprasidone in the Management of Schizophrenia: The QT Interval Issue in Context
By Taylor D.
CNS Drugs, Vol. 17, Iss. 6, 2003-01 ,pp. :
Access to resources
Recommend
Ziprasidone shows advantages in schizophrenia
Inpharma, Vol. 1, Iss. 1358, 2002-01 ,pp. :
Ziprasidone effective in treatment-resistant schizophrenia
Inpharma, Vol. 1, Iss. 1522, 2006-01 ,pp. :
Ziprasidone good value for schizophrenia exacerbations
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 535, 2007-01 ,pp. :
Spotlight on Ziprasidone in Schizophrenia and Schizoaffective Disorder
By Gunasekara N.S. Spencer C.M. Keating G.M.
CNS Drugs, Vol. 16, Iss. 9, 2002-01 ,pp. :